Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.
复制标题
通过靶向重新编程的代谢来克服化疗耐药性：胰腺导管腺癌的致命弱点。
DOI：
10.1007/s00018-021-03866-y
复制
发表时间：
2021
影响因子：
8
通讯作者：
Liang Chen
中科院分区：
文献类型：
--
作者：
Tuerhong Abudureyimu;Xu Jin;Shi Si;Tan Zhen;Meng Qingcai;Hua Jie;Liu Jiang;Zhang Bo;Wang Wei;Yu Xianjun;Liang Chen
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death due to its late diagnosis that removes the opportunity for surgery and metabolic plasticity that leads to resistance to chemotherapy. Metabolic reprogramming related to glucose, lipid, and amino acid metabolism in PDAC not only enables the cancer to thrive and survive under hypovascular, nutrient-poor and hypoxic microenvironments, but also confers chemoresistance, which contributes to the poor prognosis of PDAC. In this review, we systematically elucidate the mechanism of chemotherapy resistance and the relationship of metabolic programming features with resistance to anticancer drugs in PDAC. Targeting the critical enzymes and/or transporters involved in glucose, lipid, and amino acid metabolism may be a promising approach to overcome chemoresistance in PDAC. Consequently, regulating metabolism could be used as a strategy against PDAC and could improve the prognosis of PDAC.
